What you must know:

– Amgen, a world chief in biotechnology, is embarking on a groundbreaking enterprise: Undertaking Freyja.

– The brand new initiative will harness the ability of an NVIDIA DGX SuperPOD, named after the Norse goddess of prophecy, to speed up drug discovery and growth via AI-powered insights from one of many world's largest human knowledge units.

Enhance drug discovery utilizing NVIDIA DGX SuperPOD-powered perception

• Atlas of Human Variety: Freyja will map the panorama of human genetic variation, creating a useful atlas for figuring out drug targets and disease-specific biomarkers. This may pave the way in which for customized medication, the place remedies are tailor-made to particular person sufferers based mostly on their distinctive genetic make-up.
• Revolution in precision medication: Outfitted with Freyja's AI capabilities, Amgen researchers will develop superior precision medication fashions, doubtlessly enabling the creation of individualized therapies for a variety of significant illnesses.
• Diagnostics made simple: By figuring out novel biomarkers, Freyja will allow the event of correct and environment friendly diagnostics for monitoring illness development and response to remedy.

Unleash the ability of information

• DGX SuperPOD: A computing powerhouse, SuperPOD options 248 NVIDIA H100 Tensor Core GPUs, permitting Amgen to coach state-of-the-art AI fashions in days as a substitute of months. This dramatically accelerates the tempo of information evaluation and discovery.
• 200 petabytes of insights: Freyja will leverage deCODE genetics' huge library of anonymized human knowledge, which spans greater than 200 petabytes and contains almost 3 million people. This unparalleled useful resource offers distinctive perception into human range and its position in well being and illness.

“Freyja embodies our dedication to harnessing the convergence of expertise and biotechnology. By combining our world-class human knowledge with NVIDIA's superior AI expertise, we’re poised to unlock a brand new period of drug discovery,” mentioned David M. Reese, Chief Know-how Officer of Amgen.